## **Core Concept**
Somatostatin, also known as growth hormone-inhibiting hormone (GHIH) or somatotropin release-inhibiting factor (SRIF), is a peptide hormone that regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G protein-coupled somatostatin receptors and inhibition of the release of numerous secondary hormones. Its primary role is to inhibit the release of growth hormone from the anterior pituitary gland.

## **Why the Correct Answer is Right**
Somatostatin has several inhibitory effects on hormone secretion and gastrointestinal functions. It inhibits the release of growth hormone, thyroid-stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), insulin, and gastrin, among others. It also decreases gastrointestinal motility and secretion. Given these actions, the correct answer can be deduced by understanding which option does not align with known effects of somatostatin.

## **Why Each Wrong Option is Incorrect**
- **Option A:** If this option describes an inhibitory effect on a hormone or a physiological process known to be influenced by somatostatin, it would be incorrect because it aligns with somatostatin's actions.
- **Option B:** Similar to Option A, if this describes an action consistent with somatostatin's effects, it would be incorrect for the same reason.
- **Option D:** If this option also aligns with known effects of somatostatin, it too would be incorrect.

## **Clinical Pearl / High-Yield Fact**
A key clinical use of somatostatin and its analogs (like octreotide) is in the management of conditions like acromegaly (due to excess growth hormone), certain types of tumors (e.g., carcinoids), and severe diarrhea. Remembering that somatostatin primarily acts to inhibit hormone release can help in understanding its therapeutic applications.

## **Correct Answer:** D. Increased insulin secretion.